NCT05245396View on ClinicalTrials.gov

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Healthy
Interventions
DRUG

Ref (TF2)

Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

DRUG

Evobrutinib MR-T1

Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

DRUG

Evobrutinib MR-T2

Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.

DRUG

Evobrutinib MR-T3

Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.

DRUG

Evobrutinib MR-T4

Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.

DRUG

Evobrutinib MUPS-C1

Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.

DRUG

Evobrutinib MUPS-C2

Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.

DRUG

Evobrutinib MUPS-C3

Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.

DRUG

Evobrutinib MUPS-C4

Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.

DRUG

Evobrutinib MR-T adapated

Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.

Trial Locations (1)

NG11

Quotient Clinical Ltd, Nottingham

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY